Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
24.18
-1.59 (-6.17%)
At close: Feb 4, 2026, 4:00 PM EST
24.18
0.00 (0.00%)
After-hours: Feb 4, 2026, 6:03 PM EST
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $509.85 million as of February 4, 2026. Its market cap has increased by 203.23% in one year.
Market Cap
509.85M
Enterprise Value
240.25M
1-Year Change
203.23%
Ranking
Category
Stock Price
$24.18
Market Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $509.85M, a decrease of -87.65%. That is a compound annual growth rate of -36.31%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 3, 2026 | 547.46M | -16.28% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | 4.13B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Gossamer Bio | 527.72M |
| Forte Biosciences | 521.93M |
| Contineum Therapeutics | 520.91M |
| Ginkgo Bioworks Holdings | 509.82M |
| Tenax Therapeutics | 507.54M |
| Zevra Therapeutics | 506.68M |
| 4D Molecular Therapeutics | 506.22M |
| Vor Biopharma | 503.36M |